NCT00033228

Vaccine Therapy in Treating Patients With Stage IV Melanoma

A Phase I/II Pilot Study Of Intranodal Delivery Of A Plasmid DNA (Synchrovax SEM Vaccine) In Stage IV Melanoma Patients

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Mannkind Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV melanoma.

Detailed description

OBJECTIVES: * Determine the maximum tolerated dose of intranodal Synchrovax SEM plasmid DNA vaccine in patients with stage IV melanoma. * Determine the safety and tolerability of this drug in these patients. * Determine the immunological response, as measured by changes in frequency of T cells specific against vaccine-encoded epitopes before and after treatment, in patients treated with this drug. * Determine the clinical response, as measured by lactic dehydrogenase levels and radiologic assessment of lesions, in patients treated with this drug. OUTLINE: This is a multicenter, dose-escalation study. Patients receive Synchrovax SEM plasmid DNA vaccine by continuous intranodal infusion on days 1-4. Treatment repeats every 14 days for up to 4 courses in the absence of unacceptable toxicity. Patients with evidence of stable or responding disease are eligible for 4 additional courses of treatment. Cohorts of 6 patients receive escalating doses of Synchrovax SEM plasmid DNA vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. Patients are followed at 10 days after the last dose of study drug. PROJECTED ACCRUAL: A total of 6-18 patients will be accrued for this study.

Conditions

• Melanoma (Skin)

Interventions

Type	Name	Description
BIOLOGICAL	MKC1106-MT	Cancer Vaccine, Immunotherapy, 500 ug
BIOLOGICAL	MKC1106-MT	Cancer Vaccine, Immunotherapy, 1000 ug
BIOLOGICAL	MKC1106-MT	Cancer Vaccine, Immunotherapy, 1500 ug

Timeline

• Start date: 2002-01-01
• Primary completion: 2003-03-01
• Completion: 2003-04-01
• First posted: 2003-01-27
• Last updated: 2011-05-12

Locations

5 sites across 1 country: United States